Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents.
Joshua WolfMark J AbzugRachel L WattierPaul K SueSurabhi B VoraPhilip ZachariahDaniel E DulekAlpana WaghmareRosemary OliveroKevin James DownesScott H JamesSwetha G PinnintiApril YarbroughMargaret L AldrichChristine E MacBrayneVijaya L SomaSteven P GrapentineCarlos R OliveiraMolly HayesDavid W KimberlinSarah B JonesLaura L BioTheodore H MortonJane S HankinsGabriela M MaronKathryn TimberlakeJennifer L YoungRachel C OrschelnHayden T SchwenkDavid L GoldmanHelen E GrovesW Charles HuskinsNipunie S RajapakseGabriella S LambAlison C TribbleElizabeth C LloydAdam L HershEmily A ThorellAdam J RatnerKathleen ChiotosMari M NakamuraPublished in: Journal of the Pediatric Infectious Diseases Society (2021)
Based on evidence available as of December 20, 2020, the panel suggests against routine administration of monoclonal antibody therapy (bamlanivimab, or casirivimab and imdevimab), for treatment of COVID-19 in children or adolescents, including those designated by the FDA as at high risk of progression to hospitalization or severe disease. Clinicians and health systems choosing to use these agents on an individualized basis should consider risk factors supported by pediatric-specific evidence and ensure the implementation of a system for safe and timely administration that does not exacerbate existing healthcare disparities.